HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Sutro Biopharma (NASDAQ:STRO) with a maintained price target of $12.
May 14, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Sutro Biopharma with a $12 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in the stock's potential for growth. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100